NP CHRONICLES
Clinical Education for NP Students & New Grads
CLINICAL UPDATE • NEUROLOGY / WOMEN'S HEALTH
Annual Migraine Screening Recommended for Women of All Ages
Nearly 1 in 4 women will experience migraine at some point in her life — yet the majority never receive an accurate diagnosis or evidence-based treatment for it. In December 2025, the American Headache Society (AHS) issued a position statement addressing that gap head-on: routine, annual migraine screening for girls and women from adolescence through menopause, built into preventive care the same way we already screen for depression or cervical cancer.
This post breaks down why AHS made this call, what the screening tool actually looks like, and how to fold a 2-minute questionnaire into your well-woman visits without adding meaningful time to your day.
Why Migraine Meets the Bar for Population Screening
Migraine affects women roughly three times as often as men, a gap that emerges at puberty and is driven largely by hormonal shifts. Attacks cluster around the perimenstrual window, prevalence climbs through perimenopause, and symptoms typically ease after natural menopause. Compared with men, women also report more intense pain, longer attacks, slower recovery, and a higher likelihood the disease becomes chronic.
The numbers behind that burden are substantial. Globally, one-year migraine prevalence sits at 15.2%, with a lifetime cumulative incidence of 43% in women versus 18% in men. Migraine is most common between ages 25 and 54, and among women under 50 it is the single leading cause of years lived with disability — worth over 9.8% of all disability-years in girls and women aged 15 to 49. More than 90% of people with migraine say it interferes with their education, career, or social life, and in the CaMEO study, migraine symptoms were directly tied to relationship strain: 16.8% of respondents said they weren't currently in a romantic relationship because of their symptoms, and 3.2% had delayed, forgone, or limited childbearing because of migraine.
AHS applied the standard criteria used to justify any population-level screening program — and migraine checks every box: it's highly prevalent, causes significant morbidity, carries major economic and social costs, has a validated screening tool available, and has effective treatments once diagnosed. That combination is what makes the "screen everyone, every year" recommendation different from a routine awareness campaign.
The Cost of Getting It Wrong
Migraine's annual economic burden in the US is estimated at $78 billion — and misdiagnosis inflates that further. A 2025 study comparing patients with misdiagnosed migraine to those correctly diagnosed found substantially higher healthcare utilization across the board: nearly 6 times more neurologist visits, more than double the emergency department visits, and higher rates of inpatient admissions and prescription fills. Costs followed the same pattern, with neurologist visit costs more than 4 times higher in the misdiagnosed group. Getting the diagnosis right the first time isn't just better for the patient — it measurably reduces downstream healthcare spending.
Clinical Bottom Line
Migraine is common, underdiagnosed, and treatable — which is exactly the profile that justifies routine screening. A validated 3-question tool, completed in under 2 minutes, can be built into any well-woman visit without needing neurology-level expertise to administer or score it.
The Diagnostic Gap Screening Is Meant to Close
Despite diagnostic criteria for migraine having existed for nearly 40 years, most affected patients never complete the full path from symptom to treatment. In one US population-based study, only about 1 in 4 people (26.3%) with episodic migraine and associated disability actually consulted a provider, received a migraine diagnosis, and used a treatment specifically indicated for migraine attacks. Many patients simply don't realize their headaches meet diagnostic criteria — they assume it's "just a bad headache" and never bring it up.
That's the gap annual screening is designed to close. Rather than waiting for a patient to volunteer that their headaches are disabling, screening puts the question in front of every patient, every year, during a visit they're already attending.
The AHS Recommendation: What to Actually Do
The AHS position statement recommends incorporating migraine screening into routine health evaluations — annually, from adolescence through menopause — and reimbursing it the same way other preventive women's health services are reimbursed. While the recommendation is framed around girls and women because of their disproportionate burden, it doesn't exclude screening boys and men; it simply reflects where the unmet need is greatest.
Because the full International Classification of Headache Disorders (ICHD-3) criteria are too long and complex for routine use outside neurology, AHS recommends a much shorter, validated alternative: the ID Migraine screener.
The ID Migraine Screener
ID Migraine is a self-administered, 3-question tool that patients can complete in under 2 minutes, before or during a visit, with no clinician time required to administer it — only to interpret the result.
| During the past 3 months, did you have any of the following with your headaches? | Response |
|---|---|
| Headaches limited your ability to work, study, or do what you needed to do on at least 1 day | Yes / No |
| You felt nauseated or sick to your stomach | Yes / No |
| Light bothered you a lot more than when you don't have headaches | Yes / No |
A "yes" answer to 2 or more of the 3 questions is a positive screen. In a systematic review and meta-analysis of 13 studies covering nearly 5,900 participants, ID Migraine showed a pooled sensitivity of 84% and specificity of 76% — strong enough for a brief screening tool, and notably useful for ruling migraine out when the result is negative.
Case From Practice
A 29-year-old presents for her annual well-woman visit with no headache complaints on her intake form. As part of routine screening, she completes the ID Migraine questionnaire while waiting to be seen and answers "yes" to all three items — she's missed work due to headaches, feels nauseated during episodes, and finds light intolerable. She hadn't mentioned any of this because she assumed "everyone gets bad headaches sometimes." The positive screen prompts a focused history consistent with episodic migraine without aura. She's started on an evidence-based acute treatment and referred for follow-up, a diagnosis that would likely have gone unaddressed for years without the screening prompt.
Screening Is Not the Same as Diagnosis
A positive ID Migraine screen tells you further evaluation is warranted — it doesn't replace clinical judgment. Secondary headache disorders (those caused by an underlying condition rather than a primary headache syndrome) still need to be ruled out before treatment begins. Depending on comfort level, a positive screen can lead to an in-visit discussion, a dedicated follow-up appointment, or referral to a specialist.
Nuance to Watch
Don't let "positive screen" become "migraine confirmed" in your documentation shorthand. Red flags — sudden severe onset ("thunderclap"), new headache after age 50, neurologic deficits, headache with fever or stiff neck, or a change in a previously stable headache pattern — still warrant a secondary headache workup regardless of ID Migraine results.
Implementation: Making Screening Actually Happen
The AHS statement is candid about the barriers to rolling this out: building screening questions into the EMR, giving patients time to complete the questionnaire before being seen, managing newly identified patients, and addressing reimbursement gaps for screening-related services all take real effort. Their proposed model mirrors how many practices already handle PHQ-9 depression screening — a brief, self-scored questionnaire completed in the waiting room or via patient portal, with results documented directly in the chart for the clinician to review at the visit.
For clinicians who want a structured way to build migraine management skills, the National Headache Foundation offers PCMigraine, a free educational mobile app aimed at primary care and non-neurology settings.
Board Prep: Key Points to Lock In
- AHS (December 2025 position statement, published in Headache, Feb 2026) recommends annual migraine screening for girls and women from adolescence through menopause
- Lifetime cumulative migraine incidence: 43% in women vs. 18% in men; migraine is the leading cause of years lived with disability in women under 50
- The recommended screening tool is ID Migraine — a 3-question, self-administered screener completed in under 2 minutes
- A positive screen = "yes" to at least 2 of the 3 ID Migraine questions
- Pooled accuracy: ~84% sensitivity, ~76% specificity across a meta-analysis of 13 studies
- A positive screen prompts further evaluation — it is not itself a diagnosis, and secondary headache causes must still be excluded
- Misdiagnosed migraine drives substantially higher healthcare utilization and cost than correctly diagnosed migraine, reinforcing the value of accurate, timely screening
Board Prep Quiz
Migraine Screening in Women
Question 1 of 6
You scored
Frequently Asked Questions
Why does the American Headache Society recommend annual migraine screening for women?
Migraine is highly prevalent, disproportionately affects women, causes significant disability, and is frequently underdiagnosed — despite having a fast, validated screening tool and effective treatments available. That combination meets the standard criteria used to justify routine population-level screening.
What is the ID Migraine screener and how is it scored?
ID Migraine is a self-administered, 3-question tool asking whether headaches over the past 3 months limited activity, caused nausea, or made light bothersome. Answering "yes" to 2 or more of the 3 questions is considered a positive screen for migraine.
Is a positive migraine screen the same as a diagnosis?
No. A positive ID Migraine screen indicates further evaluation is warranted, but secondary headache disorders still need to be ruled out before migraine is confirmed as the diagnosis and treatment begins.
Why are women affected by migraine more than men?
Migraine affects women about three times as often as men, a difference that emerges at puberty and is largely driven by hormonal changes. Attacks are more frequent during the perimenstrual window, and prevalence rises further during perimenopause before declining after natural menopause.
What happens when migraine is misdiagnosed?
Misdiagnosed migraine is associated with significantly higher healthcare utilization and cost compared with correctly diagnosed migraine, including more emergency department visits, more neurologist visits, and higher prescription and inpatient costs. Accurate, timely diagnosis reduces both patient burden and unnecessary healthcare spending.
References
Schwedt TJ, Starling AJ, Ailani J, et al. Routine migraine screening as a standard of care for women's health: a position statement from the American Headache Society. Headache. 2026;66(2):511-516.
Kuruvilla DE, Hutchinson S, Moriarty M, et al. Understanding migraine throughout a woman's life and the role of calcitonin gene-related peptide: a narrative review. Womens Health (Lond). 2025;21:17455057251376878.
Kim JR, Park TJ, Agapova M, et al. Healthcare resource use and costs associated with the misdiagnosis of migraine. Headache. 2025;65(1):35-44.
Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology. 2003;61(3):375-382.
Cousins G, Hijazze S, Van de Laar FA, Fahey T. Diagnostic accuracy of the ID Migraine: a systematic review and meta-analysis. Headache. 2011;51(7):1140-1148.
Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2019;59(8):1286-1299.
This post is for clinical education purposes for NP students and new graduates and is not a substitute for individualized clinical judgment or institutional protocol.
